You will receive alerts when there are new announcements on Paradigm Biopharmaceuticals Ltd
Only registered members can use this feature.
Paradigm Biopharmaceuticals Ltd (ASX:PAR) is a late-stage drug development company with the mission to develop and commercialise pentosan polysulphate sodium for the treatment of pain associated with musculoskeletal disorders.
Paradigm will be focused on Phase 3 trials of its drug Zilosul® during 2021, COO Jeannie Joughin told Proactive.
Copyright © Proactive 2021.
All Rights Reserved - Proactive Australia PTY LTD ACN:132787654 ABN:19132787654.